Abstract 234MO
Background
Young age is associated with increased risk of recurrence in hormone receptor (HR)-positive early breast cancer (eBC). Lack of adherence to endocrine therapy (ET) has been hypothesized as a reason for the lower survival rates observed in younger patients, but the potential survival benefits of improving adherence to ET in young patients remains unknown.
Methods
In this nationwide cohort study, we used data from the French National Health Data System and causal inference methods to estimate the potential gains in 5-year disease-free survival (DFS) achievable by improving ET persistence in different age groups of women diagnosed with HR-positive eBC. We tested three definitions of ET persistence, which allowed treatment breaks of 30, 90, or 180 days.
Results
A total of 121,852 patients with HR-positive eBC were included in the analyses, of whom 29.9% were younger than 50 years and 1.8% were younger than 34 years at diagnosis. Younger patients had lower DFS and were more likely to discontinue ET than older patients. In patients diagnosed before age 34, strict ET persistence (no 30-day break) improved 5-year DFS rates from 75.8% to 81.4% (5.6 percentage-points, 95% CI: 2.5-8.8) compared to observed persistence. ET persistence strategies allowing for 90- and 180-day breaks reduced the 5-year DFS benefit in this subgroup of patients to 1.3 (95% CI: 0.0-2.5) and 1.9 (95% CI: 0.4-3.5) percentage-points, respectively, compared to observed persistence. In contrast, DFS benefits of improved ET persistence in older patients did not exceed 1.2 percentage-points, compared to observed persistence, regardless of the persistence definition.
Conclusions
The survival benefit that could be achieved with strict ET persistence in women below 34 years with HR-positive eBC highlights the need for tailored strategies to improve ET persistence in this population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
French National Cancer Institute (INCa), M.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
LBA17 - Survival outcome of neoadjuvant endocrine therapy + trastuzumab and pertuzumab (ET+T+P) vs. de-escalated chemotherapy (CT)+T+P in hormone receptor positive (HR+)/HER2+ early breast cancer (EBC): WSG-TP-II trial
Presenter: Oleg Gluz
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
239MO - TILs and overall survival (OS) in HER2+ early breast cancer (eBC): 10-year (yr) updated analysis of the ShortHER trial
Presenter: Maria Vittoria Dieci
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA15, LBA16, LBA17 and 239MO
Presenter: Fatima Cardoso
Session: Mini oral session: Breast cancer, early stage
Resources:
Slides
Webcast